PT  - JOURNAL ARTICLE
AU  - Ulrich Moser
TI  - Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?
AID  - 10.1136/bcr-2021-243072
DP  - 2021 Jul 01
TA  - BMJ Case Reports
PG  - e243072
VI  - 14
IP  - 7
4099  - http://casereports.bmj.com/content/14/7/e243072.short
4100  - http://casereports.bmj.com/content/14/7/e243072.full
SO  - BMJ Case Reports2021 Jul 01; 14
AB  - Central pain after stroke due to brainstem infarction is very rare. Treatment is difficult and specific guidelines are lacking. This is the report of a 61-year-old female patient who, after a posterolateral left medulla oblongata insult with incomplete Wallenberg syndrome, subsequently developed a burning and tingling pain in the contralateral leg and a burning and shooting pain in the ipsilateral face in trigeminal branches 1 and 2. More than 3 years of therapy with amitriptyline, gabapentin, pregabalin and various grade II and III opioids was ineffective or showed intolerable side effects. The administration of tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio improved the pain situation and quality of life quickly and permanently. The encouraging results in the present case may suggest that treatment with medical cannabis should be considered in similar cases when standard therapies are insufficient.